Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News in Brief
  • Published:

News In Brief

Nature Biotechnology volume 22, pages 1493–1494 (2004)Cite this article

An Erratum to this article was published on 01 April 2005

An Erratum to this article was published on 01 January 2005

This article has been updated

TKT victorious

On October 21, the UK's House of Lords ruled that the version of erythropoietin (EPO) developed by Transkaryotic Therapies (TKT), of Cambridge, Massachusetts, does not infringe the patent of the drug's originator, Amgen of S. San Francisco, California. Previously, the UK Patents Court had declared that TKT infringed on Amgen's patent, a ruling that was later reversed by the Court of Appeal in 2002 and which the House of Lords has now upheld, leaving TKT free to market its version of EPO in the UK (see Nat. Biotechnol. 20, 863–865, 2002). TKT's endogenous gene activation technology was not covered by Amgen's patent, said the Court of Appeal in a previous ruling, although Amgen's original patent itself was valid. In a surprise ruling, and a blow for Amgen, however, the House of Lords has also reversed the decision to consider Amgen's patent valid because it was too broad.. “Biotech companies have to be very careful in how they define their inventions, especially if they are claiming around a DNA sequence,” comments Pen ny Gilbert, a partner in the Biopharma Group at Bristows, a specialist IP law company in London. Such a case shows that technology is running ahead of patent law, and the Lords' ruling is an attempt to catch up, she adds. The ruling demonstrates that companies developing their own technologies to produce biologics, could get around some of the older patents. SA

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 01 January 2005

    Nat. Biotechnol. 22, 1493 (2004) On page 1493, paragraph 1, line 7, mentions that “The Washington, DC-based Biotechnology Industry Organization (BIO) is gobbling up two agriculture-and-food oriented communication groups—the Council for Biotechnology Information (CBI)... and the Brussels-based Crop Life International (CLI).

Rights and permissions

Reprints and permissions

About this article

Cite this article

News In Brief. Nat Biotechnol 22, 1493–1494 (2004). https://doi.org/10.1038/nbt1204-1493

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1204-1493

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing